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Abstract The diagnosis of parathyroid carcinomas is often
difficult. HRPT2 mutations have been identified in familial
[hyperparathyroidism-jaw tumor (HPT–JT) syndrome] and
sporadic parathyroid carcinomas, supporting that HRPT2
mutations may confer a malignant potential to parathyroid
tumors. In this study, we report the clinical, histopatholog-
ical, and genetic investigation of two unrelated cases, whom
had apparently sporadic malignant parathyroid tumors,
initially diagnosed as adenomas. In one case, the differential
diagnosis was complicated by cervical seeding of parathy-
roid tumor cells. Genetic studies identified de novo HRPT2
germline mutations in cases 1 (c.518_521delTGTC [p.
Ser174LysfsX27]) and 2 (c.226 C>T [p.Arg76X]), unveiling
the hereditary HPT-JT syndrome in both patients. Further-
more, the identification of somatic mutations in the patients
parathyroid tumors provided evidence for complete inacti-
vation of the HRPT2 gene, which was consistent with the
tumor malignant features. The sensitivity of parafibromin
immunostaining to detect HRPT2 mutations was limited.
The present data suggests that patients with apparently
sporadic parathyroid carcinomas, or parathyroid tumors with
atypical histological features, should undergo molecular
genetic testing, as it may detect germline HRPT2 mutations.
Establishing the diagnosis of hereditary HPT-JT syndrome is
relevant for clinical counseling and management of the
carriers and their relatives.
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Introduction
Primary hyperparathyroidism (HPT) is usually caused by a
parathyroid adenoma, less commonly by parathyroid
hyperplasia, and rarely by parathyroid carcinoma (0.5% to
5.2%) [1–4].
Parathyroid carcinomas are potentially life-threatening
tumors. The management of these aggressive neoplasms is
primarily surgical, with en bloc tumor resection and
ipsilateral thyroid lobectomy and resection of adjacent soft
tissues being the recommended as mode of therapy [3–6].
However, the diagnosis of parathyroid carcinoma is often
challenging. Recent criteria indicate that the unequivocal
diagnosis of parathyroid carcinoma requires the evidence of
vascular invasion, perineural space invasion, capsular
penetration with growth into adjacent tissues, and/or
metastases [1]. Other criteria, such as trabecular growth
pattern, fibrous bands, and mitotic figures, although
common in parathyroid carcinomas, are not a definitive
evidence of malignancy [1, 2, 4, 6]. It is, thus, common that
the diagnosis of malignancy is made retrospectively
following recurrence of the disease.
Sixty-seven to 100% (mean=77%) of parathyroid
carcinomas harbor inactivating mutations of the HRPT2
gene, as opposed to a small minority of adenomas [7–9].
Up to 33% of the mutations detected in apparently
sporadic parathyroid carcinomas have been found to be
of germline origin [10, 11], thus representing the hered-
itary hyperparathyroidism–jaw tumor (HPT-JT) syndrome
(MIM ID #145001). This autosomal dominant disorder is
characterized by the occurrence of parathyroid tumors,
which are carcinomas in approximately 15% of patients,
and ossifying fibromas of the mandible and/or the maxilla
(~30% of the patients). Some HPT-JT patients may also
develop uterine tumors and renal abnormalities such as
Wilms’ tumors, hamartomas, and polycystic disease [11–
14]. However, in some of these families, parathyroid
tumors may be the only clinical manifestation, and this
variant of the HPT-JT syndrome is designated as familial
isolated hyperparathyroidism (FIHP). FIHP is a genetical-
ly heterogeneous disease, which has also been related to
mutations in the MEN1 and CASR genes that cause the
multiple endocrine neoplasia type 1 and the familial
hypocalciuric hypercalcemia syndromes, respectively
[15–17].
The HRPT2 gene (also designated as CDC73) maps to
chromosome 1q31.2 and consists of 17 exons, which
encode a 531-amino acid ubiquitously expressed protein
termed parafibromin [18]. Parafibromin is a component of
the RNA polymerase II-associated factor 1 complex and
has been suggested to induce cell cycle arrest, by
integrating repressive histone H3 methylation during
transcription, for cyclin D1 downregulation [19, 20].
Up to 52 heterozygous germline HRPT2 mutations have
already been reported in HPT-JT and FIHP families, and the
vast majority are predicted to result in a truncated and
hence inactivated form of parafibromin [10, 11]. Moreover,
loss of heterozygosity or somatic inactivating mutations of
HRPT2 are also detected in HPT-JT-associated tumors [7–
11, 21], suggesting that HRPT2 is a tumor suppressor gene,
in keeping with the “two-hit” model of hereditary cancer
[22]. Several studies have evaluated the loss of nuclear
immunoreactivity for parafibromin as a method of assessing
HRPT2 mutation status and/or parathyroid malignancy [23–
28].
The present study reports the results of the clinical,
histopathological, and genetic investigation of two unrelat-
ed cases—cases 1 and 2—which had apparently sporadic
parathyroid tumors, initially diagnosed as adenomas, and
that presented HPT recurrence 18 and 12 months, respec-
tively, after initial surgery. The challenging diagnoses of
carcinoma in these cases are discussed. Genetic studies
identified HRPT2 germline mutations, unveiling the hered-
itary HPT-JT syndrome in both patients, which supported a
targeted genetic screening of their families.
Materials and Methods
Cases
Clinical features of patients 1 and 2 are summarized in
Table 1.
Case 1
A 23-year-old female patient was referred to the hospital to
evaluate a lower back pain in March 2006. Lumbar spine
computed tomography (CT) scan revealed osteoporosis, and
bone scintigraphy showed diffuse skeletal uptake. Biochemistry
values were: serum calcium 12 mg/dl [reference interval (RI)
8.4–10.2 mg/dl], parathyroid hormone (PTH) 230 pg/ml (RI
12–65 pg/ml), serum phosphate 1.9 mg/dl (RI 2.3–4.7 mg/dl),
urinary calcium 328 mg /24 h (RI 100–300 mg/24 h), urinary
phosphate 835 mg/24 h (RI 400–1,300 mg/24 h), alkaline
phosphatase 1,043 UI/l (RI 40–150 UI/l), and 25 OH vitamin D
9.5 ng/ml (RI 9–45 ng/ml). Neck ultrasound showed an
extrathyroidal posterior right inferior nodule compatible
with a parathyroid adenoma. She was diagnosed with
primary hyperparathyroidism and submitted to right
inferior parathyroidectomy. A parathyroid tumor, weighing
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3 g and measuring 3.0×2.5×2.0 cm, was excised with
intraoperative capsule rupture. Microscopically, the mitotic
count was low, and no extracapsular tissues invasion or
cytological atypia was present, thus an adenoma was
diagnosed.
Postoperatively, she developed a hungry bone syndrome.
She was supplemented with calcium and calcitriol for
12 months. During this period, her PTH and calcium levels
progressively raised to 143 pg/ml and 8.9 mg/dl, respec-
tively. Eighteen months after surgery, PTH was 641 pg/ml
and serum calcium was 11.9 mg/dl. She presented normal
levels of prolactin, growth hormone, insulin-like growth
factor-1, adrenocorticotropic hormone, and gastrin. There
was no family history of hypercalcemia nor MEN1-
associated neoplasms. HPT-JT was suspected, and she was
found to carry a germline mutation in the HRPT2 gene. She
had no evidence of other HPT-JT tumors, such as jaw
tumors (evaluated by CT scan), renal (CT scan), or uterine
abnormalities (endovaginal ultrasound). Although imaging
studies (magnetic resonance imaging, CT scan, ultrasound,
and parathyroid scintigraphy) were repeatedly negative, she
was submitted to an en bloc resection of thyroid and
parathyroid glands, and soft subcutaneous tissues in the
neck and in the superior mediastinum. Intraoperatively,
PTH decreased from 1,043 (at baseline) to 0 pg/ml at
30 min after surgical neck tissue resection. Histology found
uncountable nodules of parathyroid tissue, partially sepa-
rated by fibrous septae, with low pleomorphism, and high
proliferative activity (Ki-67 5–8%), raising the possibility
of local seeding of the previously excised parathyroid
tumor, since rupture of its capsule had occurred during the
first surgery. The remaining three parathyroid glands
showed normal histology. She was submitted to adjunct
intensity-modulated radiation therapy (total dose 20 Gy) in
neck and superior mediastinum. Twenty months after the
second surgery and adjunct radiotherapy, she remains
normocalcemic with measurable, although stable, levels of
PTH (50–60 pg/ml). Thus, the diagnosis of carcinoma
remains disputable in this case.
Case 2
A 34-year-old female patient was referred to the hospital to
evaluate bone pain, in 2001. Together with osteopaenia, the
patient also presented nephrolithiasis, polyuria (4.9 l/day;
RI <3 l/day), constipation, asthenia, and depression.
Physical examination revealed a palpable nodule on the
lower right limit of the thyroid lobule. Biochemistry values
were: serum calcium 13.0 mg/dl, PTH 705 pg/ml, serum
phosphate 1.48 mg/dl, urinary calcium 242 mg/24 h,
urinary phosphate 540 mg/24 h, alkaline phosphatase
221 UI/l, 25 OH vitamin D 12.4 ng/ml, osteocalcin N-
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1.68 ng/ml (RI <0.28 ng/ml). Further investigations were
performed to exclude the presence of other tumors
associated with the MEN1 syndrome. Bilateral kidney
microlithiasis was present. She had no history of cervical
irradiation and no family history of hyperparathyroidism.
Complete surgical excision of the right inferior parathy-
roid gland was performed. A parathyroid tumor, weighing
3 g and measuring 3.0×3.0×1.5 cm was excised. Histo-
logically, the parathyroid neoplasm was composed pre-
dominantly by chief cells with atypia and anisocariosis.
Mitotic count was low. Incomplete capsular penetration
was present, no angioinvasion was found, and a parathy-
roid adenoma was diagnosed. After surgery, serum
calcium was normalized (9.6 mg/dl), PTH was 34 pg/ml,
and the patient initiated therapy with calcium and vitamin
D. One year later, after discontinuation of oral calcium
supplements, serum calcium was 11.2 mg/dl and PTH was
181 ng/ml. Neck ultrasound examinations revealed a
tumor with 0.9×0.8×0.7 cm adjacent to the right thyroid
lobe. In June 2004, she was submitted to right hemi-
thyroidectomy and resection of adjacent fibroadipose
tissue containing a recurrent parathyroid nodule measuring
0.9×0.6×0.2 cm. The parathyroid nodule was composed
by cellular aggregates, involved by fibrous dense tissue.
Mitotic index was low. Venous vascular invasion was
observed. A diagnosis of parathyroid carcinoma was then
established.
HPT-JT was suspected, and sequencing analysis identi-
fied a HRPT2 gene germline mutation. A complete
evaluation for the presence of other HPT-JT related tumors,
including ossifying fibromas, was negative. Two years later,
she presented again with increased levels of serum calcium
and PTH. Ultrasonography revealed a 3.3×1.9×1.0 cm
tumor at the same site of the previously removed right
thyroid lobe. Meanwhile, she developed a hypercalcemia
crisis (calcium 15.4 mg/dl) and was submitted to zoledronic
acid perfusion (4 mg IV over 15 min) with clinical
improvement. She completed the thyroidectomy, with
removal of the parathyroid neoplasia jointly with trache-
oesophageal, paratracheal, and eight upper mediastinal
lymph nodes. Local recurrence of the parathyroid carcino-
ma was diagnosed, without evidence of lymph nodes
metastasis. She underwent adjuvant neck radiotherapy
(50 Gy in 25 fractions with linear accelerator 6 Mv) and
was started on cinacalcet 90 mg tid. Currently, her serum
calcium is 12.0 mg/dl and PTH is 495 pg/ml.
Biological Samples
Venous blood samples were obtained from the two patients
and from ten of their first degree relatives, following
written informed consent. This study was approved by the
ethical committee of our institution.
Formalin-fixed paraffin-embedded samples, from the
tumors of both patients, were used for genetic and
immunohistochemical studies. Tissue from the parathyroid
tumor excised in the first surgery, four recurrence nodules
removed in the second surgery, and from a normal left
parathyroid gland, were obtained in case 1. Parathyroid
tissues from the tumor excised in the first surgery, and of its
recurrence (third surgery), were obtained in case 2. The
histopathological classification was performed by one
pathologist and confirmed by another, following the criteria
described in the World Health Organization classification of
parathyroid tumors [1].
DNA Sequence Analysis of the HRPT2 Gene
DNA from leukocytes and parathyroid specimens of cases 1
and 2 was extracted, using standard methods, and screened for
mutations in the HRPT2 gene. Seventeen pairs of primers
were used for polymerase chain reaction (PCR) amplification
of the 17 coding exons and adjoining splice junctions of the
HRPT2 gene, as previously reported [18]. Sequences of the
PCR products were determined using the Big Dye Terminator
v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA, USA) in an automated sequencer ABI PRISM 3130
Genetic Analyzer (Applied Biosystems). Primer sequences
and assays conditions are available on request. Sequences
were compared to consensus sequences obtained from the
Ensembl Genome Browser (http://www.ensembl.org) and
NCBI (http://www.ncbi.nlm.nih.gov) databases. DNA se-
quence abnormalities were confirmed by repeat PCR and
sequencing and screened in the remaining family members.
Restriction Enzyme Analysis
Mutations, found by direct sequencing, were further
confirmed by restriction endonuclease analysis. This ap-
proach was also used to confirm the segregation pattern of
each mutation in the families of cases 1 and 2 and to assess
its frequency in 50 unrelated Portuguese controls.
Immunohistochemistry
Parafibromin expression, on formalin-fixed paraffin-
embedded parathyroid specimens, was evaluated by
immunohistochemical staining, using a mouse monoclo-
nal anti-parafibromin antibody (2H1), which targets
amino acids 87–100 (encoded by exon 3 of the HRPT2
gene; sc-33638, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). Parafibromin immunostaining was
optimized using a normal parathyroid tissue, which was
also used as positive control. Antigen retrieval was done
in 3 μm deparaffinized sections by pressure cooking
(6 min) in a 0.01 M sodium citrate, pH 6.0 buffered
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solution. Primary antibody (1:600) was incubated for 1 h,
signal amplification was done with Envision™ FLEX kit
(Dako, Glostrup, Denmark), and 3,3′-diaminobenzidine
tetrahydrochloride was used as chromogen.
Results
DNA Sequencing and Restriction Enzyme Analysis
of the HRPT2 Gene
The results of DNA sequence analysis of exons 1–17 of the
HRPT2 gene, in leukocytes and parathyroid specimens
from cases 1 and 2, are summarized in Table 1.
Case 1, carried a germline heterozygous frameshift
mutation in exon 7 of theHRPT2 gene (c.518_521delTGTC),
which predicts a premature truncation of parafibromin at
codon 201 (p.Ser174LysfsX27; Fig. 1). This deletion has
been previously described in a sporadic parathyroid carcino-
ma and in a FIHP family [29, 30]. The c.518_521delTGTC
genetic change was not detected in the patient’s parents,
indicating that it was a de novo mutation. DNA sequence
analysis was also performed in an apparently normal left
parathyroid (P1-NP) and in five different tumor samples
from this patient: P1-PT1 (first surgery—parathyroid tumor),
P1-PT1onc (first surgery—parathyroid tumor oncocytic
region), P1-PT2-nod1-3 (second surgery—parathyroid tumor
recurrence nodules 1, 2, and 3). A somatic c.162C>A
heterozygous transversion in exon 2 (p.Tyr54X) was
identified in all five tumor samples, but not in the normal
parathyroid nor in the patient’s genomic DNA (Fig. 2). This
nonsense mutation, which is predicted to cause a premature
termination of translation in codon 54, has been previously
reported in three sporadic parathyroid tumors (two carcino-
mas and one adenoma) [7, 8, 31].
Case 2 carried a germline c.226C>T heterozygous
transition in exon 2 (p.Arg76X). This nonsense mutation
is expected to lead to the premature termination of the
protein at codon 76. This mutation has been reported in a
sporadic parathyroid carcinoma and in an HPT-JT family
[8, 11]. Absence of this mutation in the patient’s parents
and five siblings showed that it was a mutation. The
Fig. 1 Detection of a germline mutation in the HRPT2 gene in case 1,
who had an apparently sporadic parathyroid tumor. a DNA sequence
analysis of the HRPT2 gene in case 1 revealed a heterozygous TGTC
deletion involving codons 173 and 174 (c.518_521delTGTC), which
predicts a premature truncation of parafibromin at codon 201 (p.
Ser174LysfsX27). a–c The mutation results in the loss of Hpy188I
restriction endonuclease site (TCT/GA), thus providing a useful
diagnostic test to confirm the presence of the mutation. b, c After
amplification of a 392-bp PCR segment, cleavage of the wild-type
sequence with Hpy188I resulted in two fragments of 115 and 277 bp,
whereas the mutant sequence was not cleaved, thus corresponding to a
single fragment of 388 bp (392 bp minus the 4 bp deletion). Case 1
(individual II .1) was heterozygous for the mutant sequence, whereas
her parents, individuals I.1 and I.2, were homozygous for the wild-type
sequence, thus confirming the results of sequencing analysis, and
indicating that it was a de novo mutation. The absence of the TGTC
deletion in 100 alleles of 50 unrelated normal controls (N1, N2, and N3,
shown in b) indicates that it is not a common DNA sequence
polymorphism. The positions of size marker pUC8 (M) are indicated.
Squares represent males; circles, females; open symbols, unaffected
individual; full symbols, affected with a parathyroid tumor; arrow
indicates the proband
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patient’s 9-year-old daughter inherited the mutation, but
no HPT-JT-related clinical or biochemical abnormalities
were present. The HRPT2 gene was also analyzed in
DNA samples from the parathyroid tumor tissues,
obtained in the patient’s first (P2-PT1) and third surgery
(recurrence; P2-PT3). In both samples, this analysis
revealed an unreported c.14T>C transition in codon 5,
exon 1, which is expected to result in the substitution of
the hydrophobic leucine residue by a helix breaker proline
residue (p.Leu5Pro). Therefore, this mutation, which
affects an evolutionarily conserved amino acid residue
[in Canis familiaris (dog), Rattus norvegicus (rat), Mus
musculus (mouse), and Xenopus tropicalis (frog)], is likely
to cause a significant alteration in the structure of
parafibromin and impair its activity.
DNA sequence alterations were confirmed by restric-
tion enzyme analysis (c.518_521delTGTC, c.162C>A,
c.226C>T; Figs. 1 and 2) or repeated DNA sequence
analyses (c.14T>C). In addition, restriction enzyme
analysis of the DNA from 50 unrelated normal individ-
uals confirmed the absence of the c.518_521delTGTC
(Fig. 1) and c.226C>T germline mutations in 100 alleles.
Immunohistochemical Analysis of Parafibromin Expression
A normal parathyroid gland was used as positive control
and showed diffuse nuclear staining in >99% of chief
cells (data not shown). Parafibromin nuclear immunos-
taining was absent in almost all tumor cells (>99%) in
the parathyroid tumor excised in the first surgery
(Fig. 3a) and recurrent tumor nodules from case 1
(Fig. 3b). The immunohistochemical study in case 2,
which was performed in parathyroid tumor tissue obtained
in the third surgery (recurrence), showed an unexpected
positive nuclear parafibromin immunostaining (>99% of
parathyroid cells) with an intensity comparable to that
observed in normal parathyroid (Fig. 3d).
Discussion
In this study, we describe two unrelated cases having
clinical and histological features consistent with malignant
parathyroid tumors. In both cases, a single parathyroid
tumor was initially excised and diagnosed as sporadic
Fig. 2 Detection of a HRPT2 gene somatic mutation in parathyroid
tumor lesions from case 1. DNA sequence analysis of the HRPT2 gene
identified a somatic c.162C>A heterozygous transvertion in codon 54
(p.Tyr54X), which predicts a premature truncation of parafibromin, in
five different tumor samples from patient 1 (P1): PT1 (first surgery—
parathyroid tumor), PT1onc (first surgery—parathyroid tumor onco-
cytic region), and PT2-nod1-3 (second surgery—parathyroid tumor
recurrence nodules 1, 2, and 3). a–c The mutation results in the loss of
a RsaI restriction endonuclease site (GTA/C), thus providing a useful
test to confirm the presence of the mutation. b, c After amplification
of a 144-bp PCR segment, cleavage of the wild-type sequence with
RsaI resulted in two fragments of 93 and 51 bp, whereas the mutant
sequence was not cleaved . All five tumor samples were heterozygous
for the mutant sequence, whereas a normal parathyroid (NP), the
patient’s genomic DNA (Blood), and a normal control (N1) were
homozygous for the wild-type sequence, thus confirming the results of
sequencing analysis. The positions of size marker pUC8 (M) are
indicated
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parathyroid adenoma. However, less than 2 years later, both
patients presented with recurrent tumor disease.
In case 1, tumor capsule rupture occurred during the
initial surgery, and at the second surgery, multiple parathy-
roid tumor nodules were removed from the cervical region.
A literature review of 11 cases with recurrent/persistent
hyperparathyroidism due to parathyroid hyperplasia/adeno-
ma seeding reported that the mean time interval between
seeding and recurrence was 9.9 years (range 1–23 years)
[32]. Noteworthy, in the present case, the recurrence
occurred in 2 years after initial surgery and was associated
with a quick rise of PTH and calcium. Overall, these
evidences, together with the high proliferative rate and
fibrous septae in the recurrent tumor nodules, suggested
that this case had an atypical parathyroid neoplasm with
features consistent with parathyroid carcinoma.
In case 2, the evidence of a tumor nodule with vascular
invasion found in the second neck exploration, and the
occurrence of a third local recurrence, established the
diagnosis of parathyroid carcinoma.
Mutations in the HRPT2 gene have been found in 67–
100% of parathyroid carcinomas in three large series [7–9].
A review of all HRPT2 mutations reported in the literature
has shown that 33% of the mutations detected in apparently
sporadic parathyroid carcinomas were present at the germ-
line level [10, 11], indicating that these tumors may
represent a manifestation of occult hereditary HPT-JT
syndrome. Thus, despite the absence of a family history
of the disease in the two present cases, we searched for
HRPT2 gene mutations in their leukocyte and tumor DNA.
Case 1 carried a de novo germline frameshift mutation in
exon 7 (c.518_521delTGTC [p.Ser174LysfsX27]). DNA
sequence analysis was also performed in an apparently
normal parathyroid, and in five separate parathyroid tumor
lesions from this patient collected in the two surgeries,
including two regions of the primary parathyroid tumor and
three recurrent tumor nodules. Besides the germline
mutation, all the tumors shared the same inactivating
somatic HRPT2 nonsense mutation (c.162C>A [p.
Tyr54X]), which was absent in the normal parathyroid.
These findings indicated the inactivation of both copies of
the HRPT2 tumor suppressor gene, in the assessed tumors,
as postulated by Knudson’s two-hit model [22]. The finding
of the same somatic mutation in all tumors indicates that the
analyzed seeding nodules derived from the original tumor,
and not from another parathyroid gland. The absence of
parafibromin immunostaining in these parathyroid tumors
is consistent with the coding of a less antigenic, or less
stable, truncated parafibromin. The absence of nuclear
staining for parafibromin has been suggested as diagnostic
of parathyroid carcinomas, with a high specificity (88–
100%) and a sensitivity ranging from 31–100% [23–28].
However, in a HPT-JT context, parathyroid adenomas may
also show total HRPT2 inactivation [10, 11], and several
authors have raised concerns about the malignant potential
of these apparently “benign” familial tumors [23, 25, 28,
33]. Thus, the biallelic inactivation of HRPT2, and absence
of parafibromin nuclear staining, observed in the tumor
specimens from case 1, was helpful to define a potentially
aggressive tumor behavior.
Fig. 3 Haematoxylin and eosin
staining (H&E) and parafibro-
min immunohistochemistry
(IHC) of parathyroid tumors
from cases 1 and 2. Case 1 A
Histological evidence of tumor
capsule rupture in the first sur-
gery (H&E). A1 Slight pleo-
morphic tumor cells (H&E). A2
absence of parafibromin immu-
nostaining in the neoplastic cells
(IHC). B Multiple small recur-
rent parathyroid tumor nodules
within the peri-thyroid soft
tissue (H&E). B1 Neoplastic
cells negative for parafibromin
immunostaining in one of the
recurrent tumor nodules (IHC).
Case 2 C Angioinvasion by
neoplastic cells (H&E). D
Intense parafibromin immunos-
taining in the nuclei of the tumor
cells (D1 high power view)
(IHC)
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The genetic analysis of case 2 identified a de novo
germline nonsense mutation in exon 2 of the HRPT2 gene
(c.226C>T [p.Arg76X]). A novel HRPT2 somatic missense
mutation (c.14T>C [p.Leu5Pro]) was identified in the
DNAs from parathyroid tumor tissues obtained in the
patient’s first and third surgery. However, although the
two inactivating hits were present in tumor samples, a
positive nuclear immunostaining for parafibromin was
observed. This finding is not unexpected because the anti-
parafibromin antibody used in the present study is directed
against amino acid residues 87–100 and the p.Leu5Pro
mutation only changes amino acid residue 5. Our result is
in agreement with other studies, which reported HRPT2
missense mutations, predicted to encode full-length parafi-
bromin, which was recognized by the antibody, but was
possibly less biologically active [24, 28, 34].
The identification of cases 1 and 2 as carriers of de novo
HRPT2 germline mutations will be relevant for the clinical
counseling and management of their descendants, in particular,
for the 9-year-old daughter of patient 2, who is still an
asymptomatic carrier. The genetic testing also allowed the
exclusion of the remaining first degree familymembers (parents
and siblings) from further clinical follow-up on this issue.
The diagnosis of parathyroid carcinoma remains very
difficult: 86% of the cases are not recognized intraoper-
atively [35] and 50% of recurrent cases are not diagnosed
by the pathologists on the first parathyroid excision [36].
As shown in this study, and also reported by others [24, 25,
27, 28], the sensitivity of parafibromin immunostaining as a
diagnostic marker alone is limited. Conversely, HRPT2
genetic testing seems to be a useful tool to define a
potential malignant behavior in parathyroid tumors. In
addition, the present apparently sporadic cases underline
the importance of HRPT2 genetic testing to unveil the
hereditary HPT-JT syndrome.
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